Skip to Content

New Additions to Drugs.com for 2016

We update the Drugs.com database on a regular cycle. The following new drug information has been added this year:

Showing additions for:

Tecentriq
May 18, 2016 - Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with advanced urothelial carcinoma, the most common type of bladder cancer.

Bevespi Aerosphere
Apr 30, 2016 - Bevespi Aerosphere (formoterol fumarate and glycopyrrolate) is a long-acting beta2-adrenergic agonist (LABA) and anticholinergic combination indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Venclexta
Apr 13, 2016 - Venclexta (venetoclax) is an oral B-cell lymphoma-2 (BCL-2) inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion.

Descovy
Apr 5, 2016 - Descovy (emtricitabine and tenofovir alafenamide) is a nucleoside analog HIV-1 reverse transcriptase inhibitor (NRTI) and nucleotide reverse transcriptase inhibitor (NtRTI) fixed-dose combination for the treatment of HIV-1 infection.

Cinqair
Mar 23, 2016 - Cinqair (reslizumab) is an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma.

Taltz
Mar 23, 2016 - Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

Odefsey
Mar 7, 2016 - Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) is a fixed-dose combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), indicated as a complete regimen for the treatment of HIV-1 infection.

Briviact
Feb 24, 2016 - Briviact (brivaracetam) is an analog of levetiracetam for the treatment of partial-onset seizures in patients with epilepsy.

Zepatier
Jan 29, 2016 - Zepatier (elbasvir and grazoprevir) is a once-daily, single tablet, NS5A replication complex inhibitor and NS3/4A protease inhibitor combination for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections.

Browse additions by year:

Hide